1 ml of each dilution was plated in duplicate onto Lowenstein-Jen

1 ml of each dilution was plated in duplicate onto Lowenstein-Jensen plates and incubated at 37 °C for 4 weeks. M. tuberculosis colonies on each plate were enumerated and the results were expressed as colony formation unit per organ. Pulmonary histopathological examination.  The lungs of the mice were fixed in 10% buffered formalin and paraffin-embedded. The paraffin-embedded tissue sections were prepared and stained with haematoxylin and eosin, and then analysed by a certified pathologist. Statistical analysis.  Data were expressed as means and standard deviations. Statistical significance between the treatment groups

was calculated using Student’s t-test, and a P-value of <0.05 was considered significant. T cells play a critical role in protective immunity against CH5424802 mw Acalabrutinib ic50 mycobacterial infection. IFN-γ ELISPOT assays were performed with the splenocytes isolated from immunized mice 2 weeks after the final immunization to analyse whether Ag85A DNA vaccine could induce specific T cell responses. As expected, mice subjected

to Ag85A DNA vaccination had a significantly increased amount of T cells that secreted IFN-γ in response to Ag85A protein than mice in control groups (P < 0.05), suggesting that Ag85A DNA immunization markedly augmented the splenic functional T cell response (Fig. 1). The production of IFN-γ from mice immunized with Ag85A DNA vaccine was significantly similar to those of saline group and plasmid vector pVAX1 group (P > 0.05), but higher

than that of M. vaccae vaccine group (P < 0.05). The production of IL-4 from mice immunized with Ag85A DNA vaccine was significantly lower than those of saline group and M. vaccae vaccine control group (P < 0.05), but comparable to that of the vector group (P > 0.05) (Fig. 2). One mouse was SPTBN5 dead in each of the plasmid vector group, RFP treatment group and M. vaccae vaccine group. The survival rates of these three groups were all 90%. Mice in other treatment groups were all 100% alive. More lymphocytes, extensive lung lesions, hyperaemia congestion in alveoli with damaged construction were observed in the lung sections from mice in the plasmid vector group and the RFP group. More foamoid cells and multi-nuclei giant cells, but fewer lymphocytes were observed in the lung sections from mice in the other therapeutic groups, and the alveoli profiles showed relatively clear and normal structures (Fig. 3). The amount of live bacteria in the lungs and spleens of mice 4 weeks after the completion of the 2-month chemotherapy were determined (Fig. 4). The CFUs from lung tissues in groups 1 to 7 were 7.43, 7.39, 6.25, 6.35, 6.08, 6.05 and 6.35 logs, respectively, and CFUs from spleen tissues were 6.36, 6.38, 5.45, 5.40, 5.36, 5.10 and 5.33 logs, respectively. Compared with the control groups, Ag85A DNA treatment alone or combined with RFP or PZA reduced the pulmonary and splenic bacterial loads by 1.03 and 1.38 logs, respectively.

Comments are closed.